Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.

Sally Arai, MD, Renee Letsinger, Laura Johnston, Ginna Laport, Robert Lowsky, David Miklos, Judith Shizuru, Wen-Kai Weng, Ruby Wong, Philip Lavori, Karl Blume, Robert Negrin, Sandra Horning

Blood (2008) 112 (11): 2194.

https://doi.org/10.1182/blood.V112.11.2194.2194

Published: 2008

Journal Articles

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, Michael B. Maris, Judith Shizuru, Jose Leis, Edward Agura, Thomas Chauncey, Michael Pulsipher, Peter McSweeney, James Wade, Benedetto Bruno, Amelia Langston, Jerry Radich, Dietger Niederwieser, Karl Blume, Rainer Storb, David G. Maloney

Blood (2007) 110 (11): 1662.

https://doi.org/10.1182/blood.V110.11.1662.1662

Published: 2007

Journal Articles

Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity.

Robert Lowsky, MD, Keith Stockerl-Goldstein, MD, Ginna Laport, MD, David Miklos, MD, Sally Arai, MD, Judith Shizuru, MD, Laura Johnston, MD, Karl Blume, MD, Robert Negrin, MD, Samuel Strober, MD

Blood (2006) 108 (11): 603.

https://doi.org/10.1182/blood.V108.11.603.603

Published: 2006

Journal Articles

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Christoph Kahl, MD, Barry Storer, PhD, Marco Mielcarek, MD, Mike Maris, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, Dietger Niederwieser, MD, Peter McSweeney, MD, Benedetto Bruno, MD, Karl Blume, MD, James Wade, MD, Jose Leis, MD, PhD, Emilia Langston, MD, Michael Pulsipher, MD, Edward Agura, MD, Rainer Storb, MD

Blood (2005) 106 (11): 703.

https://doi.org/10.1182/blood.V106.11.703.703

Published: 2005

Journal Articles

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Marco Mielcarek, MD, Lauri Burroughs, MD, Wendy Leisenring, PhD, Paul Martin, MD, Razvan Diaconezcu, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, PhD, Michael Maris, MD, Judith Shizuru, MD, Karl Blume, MD, Ute Hegenbart, MD, Dietger Niederwieser, MD, Stephen Forman, MD, Benedetto Bruno, MD, Ann Woolfrey, MD, Rainer Storb, MD

Blood (2004) 104 (11): 423.

https://doi.org/10.1182/blood.V104.11.423.423

Published: 2004

Journal Articles

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

Dietger W. Niederwieser, Ute Hegenbart, MD, Brenda M. Sandmaier, MD, Michael B. Maris, MD, Monic Stuart, MD, Hildegard Greinix, MD, Catherine Cordonnier, Bernard Rio, MD, Alois Gratwohl, Thoralf Lange, MD, Wolfram Pönisch, MD, Leante Grommisch, MD, Barry Storer, MD, David Maloney, MD, Peter McSweeney, MD, Thomas Chauncey, MD, Ed Agura, MD, Karl Blume, Rainer Storb

Blood (2004) 104 (11): 3074.

https://doi.org/10.1182/blood.V104.11.3074.3074

Published: 2004

Journal Articles

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

Fabio R. Kerbauy, MD, Thoralf Lange, MD, Ted Gooley, PhD, Judith Shizuru, MD, Jerald Radich, MD, David G. Maloney, MD, Edward Agura, MD, Benedetto Bruno, MD, Elliot Epner, MD, Thomas Chauncey, MD, PhD, Karl Blume, MD, Rainer Storb, MD, Dietger Niederwieser, MD, Brenda M. Sandmaier, MD

Blood (2004) 104 (11): 2316.

https://doi.org/10.1182/blood.V104.11.2316.2316

Published: 2004

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

Journal Articles

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

Michael B. Maris, Dietger Niederwieser, Brenda M. Sandmaier, Barry Storer, Monic Stuart, David Maloney, Effie Petersdorf, Peter McSweeney, Michael Pulsipher, Ann Woolfrey, Thomas Chauncey, Ed Agura, Shelly Heimfeld, John Slattery, Ute Hegenbart, Claudio Anasetti, Karl Blume, Rainer Storb

Blood (2003) 102 (6): 2021–2030.

https://doi.org/10.1182/blood-2003-02-0482

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity.

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only